Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF
European Journal of Heart Failure2017Vol. 19(10), pp. 1284–1293
Citations Over TimeTop 10% of 2017 papers
João Pedro Ferreira, Patrick Rossignol, Jean‐Loup Machu, Abhinav Sharma, Nicolas Girerd, Stefan D. Anker, John G.F. Cleland, Kenneth Dickstein, Gerasimos Filippatos, Hans L. Hillege, Chim C. Lang, Jozine M. ter Maaten, Marco Metra, Leong L. Ng, Piotr Ponikowski, Nilesh J. Samani, Dirk J. van Veldhuisen, Aeilko H. Zwinderman, Adriaan A. Voors, Faı̈ez Zannad
Abstract
In this prospective observational study across Europe, MRAs were largely under-prescribed and frequently discontinued. Owing to these dynamic changes, outcome inferences are inconclusive.
Related Papers
- → Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction(2015)518 cited
- → Molecular Mechanisms of Mineralocorticoid Receptor Antagonism by Eplerenone(2005)38 cited
- → Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction(2022)15 cited
- → Spironolactone in the Treatment of Congestive Heart Failure(2000)7 cited
- → Spironolactone in the Treatment of Congestive Heart Failure(2000)